Nobivac KC
Active substance
ATC code
Species
Dogs.
Indications
Active immunisation of dogs against Bordetella bronchiseptica and canine parainfluenza virus for periods of increased risk to reduce clinical signs induced by B. bronchiseptica and canine parainfluenza virus and to reduce shedding of canine parainfluenza virus.
|
Onset of immunity:
|
for Bordetella bronchiseptica: 72 hours after vaccination; for canine parainfluenza virus: 3 weeks after vaccination. |
|
Duration of immunity: |
1 year |
Dose to be administered and administration route
Nasal use.
Allow the sterile solvent provided to reach room temperature (15 °C – 25 °C).
Aseptically reconstitute the lyophilisate with the solvent. Shake the vial well after addition of the solvent. Withdraw the vaccine into the syringe, remove the needle and administer 0.4 ml directly from the tip of the syringe into one nostril.
The reconstituted vaccine is an off-white or yellowish coloured suspension.
Vaccination scheme:
Dogs should be at least 3 weeks of age. When this vaccine is concurrently administered (i.e. not mixed) with another vaccine of the Nobivac series as indicated in section 4.8, dogs should not be younger than the minimum age recommended for the other Nobivac vaccine.
Unvaccinated dogs should receive one dose at least 3 weeks prior to the period of anticipated risk, e.g. temporary kennelling, in order to get protection for both vaccine agents. In order to get protection for Bordetella bronchiseptica unvaccinated dogs should receive one dose at least 72 hours prior to the period of anticipated risk (see also section 4.5 ‘Special precautions for use’).
Revaccinate annually.
Adverse reactions
Dogs:
|
Very common (>1 animal / 10 animals treated): |
Nasal discharge1. Ocular discharge1. |
|
Common (1 to 10 animals / 100 animals reacted): |
Sneezing1, cough1. |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Wheezing1. Lethargy. Vomiting. Hypersensitivity reaction, anaphylactic-type reaction2. Immune mediated haemolytic anaemia, immune mediated thrombocytopenia, immune mediated polyarthritis. |
1 Particularly observed in very young susceptible puppies. Signs are generally mild and transient, but in occasional cases may persist for up to four weeks. In animals, which show more severe signs, appropriate antibiotic treatment may be indicated.
2 Such reaction may evolve to a more severe condition, which may be life-threatening. If such reaction occurs appropriate treatment should be administered without delay
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
TRUSTED SOURCE
